Loading
A phase 2 trial in colorectal cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 is a phase 2, randomised interventional study registered as NCT07796763 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 48 participants, started 2026-11-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: Trastuzumab Rezetecan (SHR-A1811) injection; high dose; Trastuzumab Rezetecan (SHR-A1811) injection; low dose. Conditions listed: Advanced Colorectal Cancer Expressing HER2. Primary outcome: Incidence of treatment-emergent adverse events; Determination of the recommended phase 3 dose. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed unresectable, recurrent, or metastatic colorectal adenocarcinoma that is HER2-positive". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Jiangsu Hengrui Pharmaceuticals, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Jiangsu Hengrui Pharmaceuticals, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.